Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Drugs for Pulmonary/Respiratory Diseases in Phase II Clinical Development in UNITED KINGDOM

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

              Contact the Supplier

              Lead Product(s): Rpl-554

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 14, 2020

              Details:

              Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

              Contact the Supplier

              Lead Product(s): Rpl-554

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2020

              Details:

              Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function.

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy

              Contact the Supplier

              Lead Product(s): Rpl-554

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 10, 2020

              Details:

              Phase 2b dose-ranging study is evaluating nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe COPD.

              PharmaCompass__DigitalAd